TW200608991A - Chemokine combinations to mobilize progenitor/stem cells - Google Patents

Chemokine combinations to mobilize progenitor/stem cells

Info

Publication number
TW200608991A
TW200608991A TW094127548A TW94127548A TW200608991A TW 200608991 A TW200608991 A TW 200608991A TW 094127548 A TW094127548 A TW 094127548A TW 94127548 A TW94127548 A TW 94127548A TW 200608991 A TW200608991 A TW 200608991A
Authority
TW
Taiwan
Prior art keywords
stem cells
chemokine
mobilize progenitor
combinations
progenitor
Prior art date
Application number
TW094127548A
Other languages
English (en)
Chinese (zh)
Inventor
Gary J Bridger
Louis M Pelus
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of TW200608991A publication Critical patent/TW200608991A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
TW094127548A 2004-08-13 2005-08-12 Chemokine combinations to mobilize progenitor/stem cells TW200608991A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60136704P 2004-08-13 2004-08-13

Publications (1)

Publication Number Publication Date
TW200608991A true TW200608991A (en) 2006-03-16

Family

ID=35908186

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094127548A TW200608991A (en) 2004-08-13 2005-08-12 Chemokine combinations to mobilize progenitor/stem cells

Country Status (9)

Country Link
US (1) US20060035829A1 (https=)
EP (1) EP1796716A4 (https=)
JP (1) JP2008509928A (https=)
CN (1) CN101094684A (https=)
AU (1) AU2005272653A1 (https=)
BR (1) BRPI0514343A (https=)
CA (1) CA2577046A1 (https=)
TW (1) TW200608991A (https=)
WO (1) WO2006020891A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) * 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
CA2619828A1 (en) * 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
MX2008010895A (es) * 2006-02-24 2008-09-03 Genzyme Corp Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos.
EP2042503B1 (en) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
AU2007281090A1 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
CA2673719C (en) * 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
NZ702415A (en) * 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
JP2016516672A (ja) * 2013-02-28 2016-06-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 幹細胞を動員するための方法および組成物
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
CA3026154A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
CN109310733A (zh) 2016-02-23 2019-02-05 百欧林纳克斯有限公司 治疗急性骨髓性白血病的方法
JP2019507596A (ja) * 2016-02-26 2019-03-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 生着性の高い造血幹細胞
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
MX392743B (es) 2017-04-12 2025-03-12 Magenta Therapeutics Inc Antagonistas del receptor de hidrocarburo de arilo y sus usos.
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
WO2019089833A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
EP3735412B1 (en) 2018-01-03 2024-02-21 EdiGene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CA3176979A1 (en) 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
CN116789639A (zh) * 2022-03-14 2023-09-22 上海医药工业研究院有限公司 Mavorixafor的纯化方法、其盐及有关物质

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
DE69433301T2 (de) * 1993-06-08 2004-09-09 Smithkline Beecham Corp. Methoden zur erhöhung der biologischen aktivität von chemokinen
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
CA2178902A1 (en) * 1993-12-14 1995-06-22 The Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
DE60042030D1 (de) * 1999-12-17 2009-05-28 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
PT1317451E (pt) * 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
CA2419224A1 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6835731B2 (en) * 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AU2002211393B2 (en) * 2000-09-29 2007-06-28 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
EP1385865A4 (en) * 2001-04-03 2005-05-25 Applera Corp ISOLATED HUMAN KINASEPROTEINS, NUCLEIC ACID MOLECULES CODING FOR HUMAN KINASEPROTEINS AND THEIR USES
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ES2380009T3 (es) * 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
WO2003048345A1 (en) * 2001-12-07 2003-06-12 Toolgen, Inc. Phenotypic screen of chimeric proteins
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
AU2004232361A1 (en) * 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS

Also Published As

Publication number Publication date
EP1796716A4 (en) 2010-09-08
AU2005272653A1 (en) 2006-02-23
JP2008509928A (ja) 2008-04-03
EP1796716A2 (en) 2007-06-20
US20060035829A1 (en) 2006-02-16
CN101094684A (zh) 2007-12-26
WO2006020891A2 (en) 2006-02-23
WO2006020891A3 (en) 2006-07-13
CA2577046A1 (en) 2006-02-23
BRPI0514343A (pt) 2008-06-10

Similar Documents

Publication Publication Date Title
TW200608991A (en) Chemokine combinations to mobilize progenitor/stem cells
MXPA04000982A (es) Metodos para movilizar celulas progenitoras/madre.
SG165322A1 (en) Engineered anti-il-23 antibodies
WO2007095594A3 (en) Methods and compositions for enhancing engraftment of hematopoietic stem cells
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
NZ612132A (en) Immunomodulation using placental stem cells
WO2005099775A3 (en) Labeled anwexin for predicting the response to a therapeutic regimen
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
WO2008116024A3 (en) Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
EP2322557A3 (en) Compositions and methods for treating proliferative disorders
DK1846974T3 (da) Membran-elektrode samlinger til brændstofceller, deres fremstilling og anvendelse og brændstofceller indeholdende disse
MXPA05011353A (es) Compuestos heterociclicos que se unen al receptor de quimiocina con eficacia mejorada.
WO2007014169A3 (en) Anti-cd26 antibodies and methods of use thereof
MX2007000215A (es) Catalizadores para electrodos de celdas combustibles basados en platino y sus aleaciones, la preparacion y uso de los mismos, asi como las celdas combustibles que los contienen.
ZA200704260B (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
CY1111769T1 (el) Παρασκευη κυτταρων
BRPI0814931A2 (pt) Composto com atividade contra hcv, sua composição e seu uso
SG158133A1 (en) Method for reversing multiple resistance in animal cells
WO2006133398A3 (en) In vitro activated donor t-cells to promote transplant engraftment
WO2005079868A3 (en) Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
WO2007041397A3 (en) Targeted pharmaceuticals and ligands
EP1956084A4 (en) USE OF GLUCOSEISOMERASE MUTANES
Tara Karl Marx and Immanuel Kant on the Improvement of Society
HK1105369A (en) Chemokine combinations to mobilize progenitor/stem cells